Polycystic Kidney, Autosomal Dominant Clinical Trial
Official title:
An International, Multicenter, Randomized Controlled Clinical Trial Assessing the Efficacy of Ursodeoxycholic Acid as a Volume Reducing Treatment in Symptomatic Polycystic Liver Disease
Rationale: Polycystic liver disease (PLD) is a rare disorder characterized by >20 fluid-filled hepatic cysts. Polycystic livers are present in the combination with renal cysts as a manifestation of autosomal dominant polycystic kidney disease (ADPKD), or isolated in the absence of renal cysts as autosomal dominant polycystic liver disease (ADPLD or PCLD). PLD patients are confronted with symptoms caused by the mass effect of their polycystic liver every day for the rest of their life. There is no standard therapeutic option for symptomatic PLD patients. Current options are fairly invasive or their efficacy is only moderate. Preliminary data in our research lab have shown that ursodeoxycholic acid (UDCA) inhibited the proliferation of polycystic human cholangiocytes in vitro through the normalization of the intracellular calcium levels in cystic cholangiocytes. The investigators also found that daily oral administration of UDCA for 5 months to polycystic kidney disease (PCK) rats, an animal model of ARPKD that spontaneously develops hepato-renal cystogenesis, resulted in inhibition of hepatic cystogenesis. The investigators hypothesize that UDCA is an effective therapeutic tool in reducing liver volume in PLD. Objective: First, to demonstrate whether UDCA-therapy is effective in reducing total liver volume in PLD patients. Second, the investigators want to assess if UDCA modifies quality of life. Finally, the investigators want to assess safety and tolerability. Study design: International, multicenter, randomized, controlled trial Study population: 34 subjects (18 ≤age ≤ 80 years) suffering from symptomatic polycystic liver disease with underlying diagnosis of (PCLD or ADPKD), defined as ≥ 20 liver cysts on CT-scan and liver volume of ≥ 2500. Symptomatic is defined as Eastern Cooperative Oncology Group- Performance Score (ECOG-PS) ≥ 1 and having at least three out of ten PLD symptoms. Intervention: The patients will be randomized (1:1) into two groups. One group of patients will receive 15-20mg/kg/day UDCA for 24 weeks. The other group will receive standard care. Main study endpoint: Proportional change of total liver volume in UDCA treated patients versus non treated patients, as assessed by CT at baseline and 6 months.
We investigated whether ursodeoxycholic acid was able to reduce total liver volume in polycystic liver disease. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310319 -
Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt
|
N/A | |
Completed |
NCT04363554 -
The Kidneys Ability to Concentrate and Dilute Urine in Patients With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Recruiting |
NCT05521191 -
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1 | |
Completed |
NCT03687554 -
Effect of Venglustat in Patients With Renal Impairment
|
Phase 1 | |
Terminated |
NCT03523728 -
A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients
|
Phase 2/Phase 3 | |
Completed |
NCT00565097 -
Lanreotide as Treatment of Polycystic Livers
|
Phase 2/Phase 3 | |
Completed |
NCT00410007 -
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT02251275 -
Long Term Safety of Immediate-release Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 3 | |
Completed |
NCT01559363 -
A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02903511 -
Feasibility Study of Metformin Therapy in ADPKD
|
Phase 2 | |
Completed |
NCT00456365 -
Effect of Statin Therapy on Disease Progression in Autosomal Dominant Polycystic Kidney Disease (ADPKD)
|
Phase 3 | |
Recruiting |
NCT05510115 -
Feasibility of Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT02494141 -
Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
|
Phase 4 | |
Completed |
NCT04407481 -
PErfusioN, OxyGen ConsUmptIon and ENergetics in ADPKD (PENGUIN)
|
||
Completed |
NCT02847624 -
Post-Marketing Surveillance Study of Tolvaptan in Patients With ADPKD
|
||
Completed |
NCT03342742 -
Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
|
N/A | |
Completed |
NCT02656017 -
Metformin as a Novel Therapy for Autosomal Dominant Polycystic Kidney Disease
|
Phase 2 | |
Completed |
NCT04023214 -
The Role of Endothelial Dysfunction in Adult Polycystic Kidney Disease
|
||
Terminated |
NCT01589705 -
The Relation Between Uric Acid Level and Endothelial Dysfunction in Patients With Polycystic Kidney Disease
|
N/A | |
Completed |
NCT00426153 -
Octreotide in Severe Polycystic Liver Disease
|
Phase 2/Phase 3 |